DIAアカウントをお持ちの場合、サインインしてください。

サインイン

ユーザーIDをお忘れですか? or パスワードをお忘れですか?

Sheraton Philadelphia University City

2019年10月14日 (月) 午前 7:45 - 2019年10月17日 (木) 午後 5:00

3549 Chestnut Street, Philadelphia, PA 19104

Regulatory Affairs: The IND, NDA, and Post-Marketing

Learn about FDA regulations and expectations for the content, submission and review of INDs/NDAs, and the importance of regulatory strategy.

学部

Carol H. Danielson, DrPH, MS, RAC

Carol H. Danielson, DrPH, MS, RAC

President, Regulatory Advantage, LLC, United States

Ms Carol H. Danielson, Dr PH, RAC has provided regulatory expertise and leadership for more than twenty five years for drugs, biologics and medical devices from discovery through post-marketing. Her areas of specialization include regulatory strategy and submissions, clinical affairs and compliance, and quality assurance and control. Her background includes both extensive “hands on” experience and corporate level strategy activities from partnering due diligence to serving as an expert witness in the drug development process.

Drusilla  Scott, PhD, RAC

Drusilla Scott, PhD, RAC

Vice President, Regulatory Affairs, Sobi, Inc., United States

Dr. Scott has more than 30 years of experience in drug regulatory affairs in the pharmaceutical industry, and is currently at Sobi, a specialty pharmaceutical company that is building a portfolio of differentiated medicines for patients with rare conditions. She has served in a number of companies, including BDSI, Cempra, EMD, Pfizer and Parke-Davis, as a principal in constructing clinical regulatory strategies and submissions for the development of products across a range of therapeutic areas, with a focus on anti-infective drugs. She is also a certified paralegal with primary interests in administrative law and intellectual property.

最新情報や機会を逃さないで

DIAのメールを購読すれば、常に最新の業界情報やイベント情報を得ることができます。